Investing.com - Adaptimmune Therapeutics (NASDAQ:ADAP) reported on Thursday third quarter earnings that beat analysts' forecasts and revenue that topped expectations.
Adaptimmune Therapeutics announced earnings per share of $-0.04 on revenue of $1.19M. Analysts polled by Investing.com anticipated EPS of $-0.25 on revenue of $1.02M.
Adaptimmune Therapeutics shares are up 5% from the beginning of the year, still down 60.45% from its 52 week high of $13.40 set on June 1. They are under-performing the S&P 500 which is up 6.58% from the start of the year.
Adaptimmune Therapeutics shares gained 1.89% in pre-market trade following the report.
Adaptimmune Therapeutics follows other major Healthcare sector earnings this month
Adaptimmune Therapeutics's report follows an earnings beat by J&J on October 13, who reported EPS of $2.2 on revenue of $21.08B, compared to forecasts EPS of $1.98 on revenue of $20.2B.
Pfizer had beat expectations on October 27 with third quarter EPS of $0.72 on revenue of $12.13B, compared to forecast for EPS of $0.71 on revenue of $12.31B.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar